Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
← catalyst calendarNCT07773454 · readout in 712 d
Sponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-30 | estimated | When the study began enrolling |
| Primary completion | 2028-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cancer
- Pediatric Cancer
Intervention
- Drug: Zanzalintinib — also filed as XL092
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Dose-Limiting Toxicities (DLTs)
measured Up to Day 28
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
measured Up to 8 months
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed